Abstract:Objective To investigate the preventive effects of rosiglitazone on nonalcoholic steatohepatitis (NASH) rats and to explore the potential mechanisms in modulating peroxisome proliferator-activated receptor gamma (PPARγ),nuclear factor kappa B (NF-κB),and cyclooxygenase-2 (COX-2) expression.Methods Thirty male SD rats were assigned into the normal group ( n =10),the model group ( n =10),rosiglitazone prevention group [ n =10,simultaneously 4mg/( kg · d) gavage daily at beginning].Liver appearance,liver index,and histological changes were assessed.Serum tumor necrosis factor-o (TNF-c) and prostaglandin E2 (PGE2) were determined using enzyme-linked immunosorbent assay.The expressions of PPARγ,NF-κB,and COX-2 in liver were determined using immunohistochemical methods.The mRNA and protein expressions of COX-2 were disclosed by real-time polymerase chain reaction and Western blot analysis.Results Compared with the normal group,the liver index significantly increased in model group (3.92 ±0.72 vs.5.71 ± 1.05,P =0.004).HE and Masson staining showed significantly increased steatosis,inflammation,and fibrosis.The serum levels of TNF-α,PGE2 in high-fat-diet-fed rats were significantly increased ( 11.72 ± 2.47 vs.29.39 ± 5.32,P =0.002 ; 236.60 ± 24.90vs.288.24 ± 17.17,P =0.004).Immunohistochemistry showed NF-κB and COX-2 in livers were significantly elevated,but PPARγ wasdecreased in nonalcoholic steatohepatitis rats.Real-time polymerase chain reaction and Western blot found mRNA and protein expressions of COX-2 were increased in the model group (0.57 ± 0.08 vs.2.83 ± 0.24,P =0.0007 ; 0.38 ± 0.03 vs.1.00 ± 0.03,P =0.004).Compared with the model group,the expressions of PPARγsignificantly increased and the expressions of NF-κB and COX-2 significantly decreased ( mRNA:2.83 ± 0.24 vs.0.46 ± 0.11,P =0.002 ; protein: 1.00 ± 0.03 vs.0.62 ± 0.02,P =0.006 ) in the rosiglitazone prevention group.Conclusion By inhibiting NF-κB and COX-2 expressions,rosiglitazone can reduce insulin resistance and then prevent the occurrence and deve lopment of nonalcoholic steatohepatitis.

PPARγ Agonist Rosiglitazone Suppresses Renal Mpges-1/Pge2 Pathway in Db/db Mice

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

COX-2 but not mPGES-1 contributes to renal PGE2 induction and diabetic proteinuria in mice with type-1 diabetes.

Protective Effects of Rosiglitazone on Non-Alcoholic Steatohepatitis in Rats

Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression

Sex Dimorphic Actions of Rosiglitazone in Generalised Peroxisome Proliferator-Activated Receptor-Γ (Ppar-Γ)-deficient Mice

Inhibitory Effects of Rosiglitazone on Lipopolysaccharide-Induced Inflammation in a Murine Model and HK-2 Cells

Rosiglitazone Ameliorates Diabetic Nephropathy by Inhibiting Reactive Oxygen Species and Its Downstream-Signaling Pathways

Rosiglitazone Inhibitory Effect on Mesangial Cell Proliferation and Extracellular Matrix Expression Induced by Angiotensin Ⅱ

PGC-1α Ameliorates Kidney Fibrosis in Mice with Diabetic Kidney Disease Through an Antioxidative Mechanism.

Renal-Protective Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone in Ob/ob Mice.

A Ppar Gamma Agonist Inhibits Aldosterone-Induced Mesangial Cell Proliferation by Blocking Ros-Dependent Egfr Intracellular Signaling

Reduction of serum advanced glycosylation end products-peptides and monocyte chemoattractant protein-1 by rosiglitazone in type 2 diabetic rats

Rosiglitazone Reduces Diabetes Angiopathy by Inhibiting Mitochondrial Dysfunction Dependent on Regulating HSP22 Expression

Increased Susceptibility of Db/db Mice to Rosiglitazone-Induced Plasma Volume Expansion: Role of Dysregulation of Renal Water Transporters

Ectopic Overexpression Of Ppar Gamma 2 In The Heart Determines Differences In Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones In A Mouse Model Of Diabetes

Ectopic Overexpression of PPARγ2 in the Heart Determines Differences in Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones in a Mouse Model of Diabetes

Peroxisome Proliferator-Activated Receptor-γ-Agonist Blocked Angiotensin Ⅱ induced Podocyte Injury

Rosiglitazone maleate inhibits the hyperexpression of RANTES induced by advanced glycosylation end products in human renal mesangial cells (HRMC)